Opinion|Videos|January 21, 2025
CAR T and Evolving Treatment Paradigms for Early R/R MM
Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
- Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
4
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
5